Drugs / AT278
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05754424 | Feb 2023 → Jan 2024 | type 2 diabetes mellitus | Arecor Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05754424 ↗ |
| Known as | insulin aspart | “This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard...” NCT05754424 ↗ |
| Modality | Protein / enzyme biologic | “Concentrated rapid acting insulin aspart” NCT05754424 ↗ |
| Route | Subcutaneous | “Single subcutaneous injection of 0.5 U/kg” NCT05754424 ↗ |